New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory,…
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused…
Piezo Motion partnership with MEV Elektronik will deliver motion control and automation solutions to original equipment manufacturers in central and…
WARSAW, Ind., March 24, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively…
Health Canada approval continues Sientra’s international expansion and growth accelerationSANTA BARBARA, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc.…
Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task forceMIAMI, March 24, 2022 (GLOBE NEWSWIRE)…
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021…
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…
On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of…